121.62
Repligen Corp stock is traded at $121.62, with a volume of 313.44K.
It is up +0.29% in the last 24 hours and down -4.06% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$121.01
Open:
$122.12
24h Volume:
313.44K
Relative Volume:
0.39
Market Cap:
$7.47B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-392.32
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-8.06%
1M Performance:
-4.06%
6M Performance:
-17.63%
1Y Performance:
-1.33%
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RGEN
Repligen Corp
|
121.47 | 7.47B | 633.51M | -8.10M | 131.26M | -0.31 |
![]()
ISRG
Intuitive Surgical Inc
|
513.33 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
170.19 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
84.94 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
RMD
Resmed Inc
|
252.38 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
219.88 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Mar-18-25 | Initiated | Evercore ISI | In-line |
Feb-10-25 | Initiated | TD Cowen | Buy |
Dec-17-24 | Initiated | Canaccord Genuity | Hold |
Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
Jun-18-24 | Initiated | Guggenheim | Neutral |
Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-20-23 | Initiated | Wells Fargo | Overweight |
Jul-05-23 | Resumed | JP Morgan | Overweight |
Mar-28-23 | Initiated | The Benchmark Company | Buy |
Dec-14-22 | Initiated | Deutsche Bank | Hold |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-20-22 | Initiated | UBS | Buy |
Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
May-07-20 | Reiterated | H.C. Wainwright | Buy |
Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Oct-15-19 | Initiated | SVB Leerink | Outperform |
Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
Aug-23-19 | Resumed | Stephens | Overweight |
Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-17-18 | Upgrade | CL King | Neutral → Buy |
Nov-12-18 | Downgrade | CL King | Buy → Neutral |
Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
Dec-08-17 | Initiated | Citigroup | Buy |
Dec-05-17 | Initiated | JP Morgan | Overweight |
Nov-13-17 | Initiated | CL King | Buy |
Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
Jul-21-17 | Initiated | William Blair | Outperform |
Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Yousif Capital Management LLC Has $2.01 Million Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Does Repligen Corp (RGEN) Have a Strong Pricing Power? - Insider Monkey
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Parallel Advisors LLC Has $36,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen at William Blair Conference: Innovation Drives Growth By Investing.com - Investing.com Canada
Repligen at William Blair Conference: Innovation Drives Growth - Investing.com
Repligen Corp (RGEN) Stock Price Up 5% on Jun 3 - GuruFocus
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers - Yahoo Finance
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? - Yahoo Finance
Repligen Corp (RGEN) Trading Down 3.33% on May 30 - GuruFocus
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? - Yahoo Finance
Cetera Investment Advisers Has $436,000 Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp (RGEN) Stock Price Up 4.35% on May 27 - GuruFocus
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - The Manila Times
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report - TradingView
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges By Investing.com - Investing.com UK
Repligen Corporation to Present at William Blair Growth Conference - Yahoo Finance
Repligen at RBC Capital Markets: Strategic Growth Insights - Investing.com Australia
Insider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN) - GuruFocus
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Mercer Global Advisors Inc. ADV Sells 1,039 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Pioneering innovation in bioprocessing: Repligen’s growing impact in the area and symbiotic relationship with WWETB - Business Post
Why Repligen Corp Stock Might Make Sense If Bought Today - Stocksregister
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
Stifel Financial Corp Grows Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Things To Consider Before Buying Repligen Corp (NASDAQ: RGEN) - Stocksregister
Global Hollow Fiber Filtration Market Set to Witness - openPR.com
M&A activity dominates Q1, nearly 99% total med-tech deal value - BioWorld MedTech
Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com - Defense World
Investor’s Toolkit: Key Ratios for Assessing Repligen Corp (RGEN)’s Performance - DWinneX
Repligen Corporation to Present at Upcoming May Investor Conferences - Yahoo Finance
Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright - Defense World
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RG - GuruFocus
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RGEN Stock News - GuruFocus
Leerink Partnrs Has Pessimistic View of Repligen Q2 Earnings - Defense World
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare - Insider Monkey
There is no doubt that Repligen Corp (RGEN) ticks all the boxes. - Sete News
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’ - Insider Monkey
Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to “Outperform” - Defense World
BlackRock, Inc. Reduces Stake in Repligen Corp: An In-Depth Anal - GuruFocus
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) - Benzinga
Wolfe Research Upgrades Repligen Corp (RGEN) to an Outperform from a Peer perform - knoxdaily.com
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty - Yahoo Finance
Repligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock News - GuruFocus
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):